

# INPLASY

## Intravascular imaging or physiology-guided coronary revascularization in patients with multivessel coronary disease

INPLASY202420092

doi: 10.37766/inplasy2024.2.0092

Received: 21 February 2024

Published: 21 February 2024

Sun, JC<sup>1</sup>; Liu, XY<sup>2</sup>.

### Corresponding author:

Jing-Chao Sun

15990657855@163.com

### Author Affiliation:

Taizhou Municipal Hospital.

### ADMINISTRATIVE INFORMATION

**Support** - Taizhou Municipal Hospital.

**Review Stage at time of this submission** - Preliminary searches.

**Conflicts of interest** - None declared.

**INPLASY registration number:** INPLASY202420092

**Amendments** - This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 21 February 2024 and was last updated on 21 February 2024.

### INTRODUCTION

**Review question / Objective** To compare intravascular imaging and physiology-guided coronary revascularization in patients with multivessel coronary disease.

**Condition being studied** In patients with multivessel coronary disease, the best strategy to guide coronary revascularization was unclear.

### METHODS

**Participant or population** Patients with multivessel coronary lesions.

**Intervention** Intravascular imaging or physiology-guided coronary revascularization.

**Comparator** Angiographically guided coronary intervention or coronary artery bypass grafting.

**Study designs to be included** Randomized controlled trials.

**Eligibility criteria** 1) Patients: patients with multivessel coronary lesions; 2) Intervention: intravascular imaging or physiology guided coronary revascularization; 3) Control: angiographically guided coronary intervention or coronary artery bypass grafting; 4) Outcome: MACE (a composite endpoint of death, MI, and TLR); 5) Study design: RCTs.

**Information sources** PubMed, Embase, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, and grey literature databases were searched.

---

**Main outcome(s)** Primary outcome: MACE (a composite endpoint of death, MI, and TLR).

**Additional outcome(s)** Secondary outcomes: the components of the primary outcome, cardiac death, TVR, stent thrombosis, and stroke.

**Quality assessment / Risk of bias analysis** ROB2 for individually randomized, parallel-group trials is applied to included studies. GRADE assessment was used to evaluate the quality of outcomes.

**Strategy of data synthesis** All analyses for the pairwise meta-analysis were performed using STATA software and R software was used for network network meta-analysis. RRs value of each outcome and the corresponding 95% CI was calculated.

**Subgroup analysis** Subgroup analysis was performed based on intravascular imaging assessment or coronary physiology assessment. In addition, we also conducted subgroup analysis according to patients and trial characteristics.

**Sensitivity analysis** Leave-one-out meta-analysis was applied to the sensitivity analysis.

**Language restriction** No language restriction.

**Country(ies) involved** China.

**Keywords** Multivessel coronary disease; Intravascular imaging; Coronary physiology; percutaneous coronary intervention.

**Contributions of each author**

Author 1 - Jing-Chao Sun.

Email: 15990657855@163.com

Author 2 - Xuan-Yan Liu.

Email: liuxuanyan1413@163.com